Patients treated in an outpatient setting who later required admission spent an average of 12.1 days in the hospital, ...

Indian scientists have reported a major advance in cancer treatment after using artificial intelligence to redesign CAR T ...

The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...

CAR T-cell therapy re-engineers immune cells to target and eradicate high-risk blood cancers, offering potential cures where traditional chemotherapy fails. Initially requiring inpatient care due to ...

For starters, she pointed out that standard CAR-T therapy involves a lymphodepletion regimen with cyclophosphamide and ...

Patients relapsing within three months post-CAR T-cell therapy have lower response rates to BsAb therapy compared to those relapsing after six months. Elevated LDH levels and higher international ...

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...

Kite Pharma’s bicistronic CAR T-cell therapy hit the main goal of a phase 1a trial, with zero dose-limiting toxicities (DLTs) occurring in patients with advanced B-cell lymphoma (BCL). The therapy was ...

A pioneering preclinical study has shown that CAR T cell therapy-a personalized form of immunotherapy used in cancer treatment-could be a highly effective tool against atherosclerosis, the condition ...

CAR T-cell therapy is being adapted for clear cell renal cell carcinoma, targeting CAIX and CD70 to improve efficacy and safety. Early trials like COBALT-RCC and TRAVERSE show promising disease ...

BENGALURU: At a global cell therapy symposium in the city, oncologists said India offers CAR-T cell therapy at one-tenth the ...

Our immune system functions like well-equipped soldiers or guards to combat pathogens and for the most part, it does a great job! However, some viruses like herpesviruses have a cunning trick up their ...